Guido Tricot
Concepts (537)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 135 | 2022 | 2686 | 10.150 |
Why?
| Hematopoietic Stem Cell Transplantation | 25 | 2022 | 531 | 3.930 |
Why?
| Pyrazines | 19 | 2014 | 205 | 2.990 |
Why?
| Boronic Acids | 19 | 2014 | 201 | 2.990 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 33 | 2019 | 1008 | 2.770 |
Why?
| Thalidomide | 27 | 2012 | 405 | 2.680 |
Why?
| Antineoplastic Agents | 30 | 2020 | 1244 | 2.280 |
Why?
| Transplantation, Autologous | 27 | 2022 | 459 | 2.100 |
Why?
| Drug Resistance, Neoplasm | 17 | 2020 | 297 | 1.810 |
Why?
| Transplantation Conditioning | 9 | 2019 | 89 | 1.800 |
Why?
| Paraproteinemias | 8 | 2018 | 66 | 1.590 |
Why?
| Neoplastic Stem Cells | 5 | 2020 | 102 | 1.440 |
Why?
| Protease Inhibitors | 6 | 2011 | 63 | 1.320 |
Why?
| Humans | 146 | 2022 | 50276 | 1.260 |
Why?
| Venous Thrombosis | 7 | 2009 | 104 | 1.250 |
Why?
| Angiogenesis Inhibitors | 9 | 2009 | 211 | 1.180 |
Why?
| Hematopoietic Stem Cell Mobilization | 5 | 2014 | 65 | 1.150 |
Why?
| Stem Cell Transplantation | 12 | 2011 | 195 | 1.150 |
Why?
| Gene Expression Regulation, Neoplastic | 13 | 2020 | 878 | 1.090 |
Why?
| Prognosis | 32 | 2021 | 2057 | 1.050 |
Why?
| Busulfan | 3 | 2019 | 18 | 1.040 |
Why?
| Alkaline Phosphatase | 5 | 2011 | 100 | 1.040 |
Why?
| Aged | 56 | 2021 | 10017 | 0.990 |
Why?
| Middle Aged | 58 | 2021 | 13149 | 0.980 |
Why?
| Melphalan | 15 | 2019 | 176 | 0.980 |
Why?
| Treatment Outcome | 39 | 2022 | 5421 | 0.910 |
Why?
| Plasma Cells | 10 | 2016 | 225 | 0.880 |
Why?
| Chromosome Aberrations | 9 | 2008 | 302 | 0.800 |
Why?
| Thromboembolism | 3 | 2009 | 58 | 0.800 |
Why?
| Male | 66 | 2021 | 27231 | 0.770 |
Why?
| Chromosomes, Human, Pair 13 | 6 | 2008 | 47 | 0.740 |
Why?
| Neoplasm Proteins | 6 | 2021 | 379 | 0.740 |
Why?
| Female | 62 | 2021 | 27910 | 0.720 |
Why?
| Immunoglobulin Light Chains | 3 | 2016 | 97 | 0.700 |
Why?
| Disease-Free Survival | 14 | 2019 | 520 | 0.690 |
Why?
| Blood Transfusion | 1 | 2018 | 123 | 0.680 |
Why?
| Bone Remodeling | 2 | 2010 | 178 | 0.670 |
Why?
| Survival Rate | 18 | 2019 | 995 | 0.670 |
Why?
| Anticoagulants | 5 | 2009 | 263 | 0.670 |
Why?
| Immunologic Factors | 5 | 2012 | 123 | 0.660 |
Why?
| Dexamethasone | 14 | 2009 | 398 | 0.640 |
Why?
| Receptors, Retinoic Acid | 2 | 2013 | 28 | 0.630 |
Why?
| Antineoplastic Agents, Alkylating | 7 | 2008 | 77 | 0.620 |
Why?
| IMP Dehydrogenase | 2 | 2006 | 5 | 0.620 |
Why?
| Mycophenolic Acid | 2 | 2006 | 17 | 0.610 |
Why?
| Proteasome Inhibitors | 6 | 2018 | 105 | 0.610 |
Why?
| Gene Expression Profiling | 17 | 2018 | 1082 | 0.600 |
Why?
| Cell Line, Tumor | 17 | 2020 | 1472 | 0.580 |
Why?
| Combined Modality Therapy | 13 | 2008 | 701 | 0.570 |
Why?
| Recurrence | 16 | 2018 | 688 | 0.570 |
Why?
| Follow-Up Studies | 20 | 2018 | 2357 | 0.560 |
Why?
| Antigens, Neoplasm | 5 | 2007 | 167 | 0.560 |
Why?
| Adult | 37 | 2018 | 13861 | 0.550 |
Why?
| Venous Thromboembolism | 3 | 2011 | 58 | 0.550 |
Why?
| Cell Proliferation | 15 | 2020 | 1117 | 0.540 |
Why?
| Up-Regulation | 5 | 2020 | 519 | 0.540 |
Why?
| Osteogenesis | 3 | 2012 | 387 | 0.520 |
Why?
| Antibodies, Monoclonal | 3 | 2015 | 534 | 0.520 |
Why?
| Disease Progression | 12 | 2019 | 867 | 0.520 |
Why?
| Apoptosis | 9 | 2019 | 1313 | 0.520 |
Why?
| Doxorubicin | 8 | 2018 | 264 | 0.510 |
Why?
| Survival Analysis | 12 | 2021 | 787 | 0.510 |
Why?
| Central Nervous System Neoplasms | 2 | 2004 | 50 | 0.510 |
Why?
| Bone Diseases | 3 | 2012 | 105 | 0.500 |
Why?
| Retrospective Studies | 16 | 2018 | 5676 | 0.490 |
Why?
| Signal Transduction | 12 | 2020 | 1801 | 0.490 |
Why?
| Thrombosis | 4 | 2012 | 255 | 0.480 |
Why?
| Myeloablative Agonists | 5 | 2014 | 36 | 0.480 |
Why?
| Transplantation, Homologous | 6 | 2004 | 165 | 0.460 |
Why?
| Oligopeptides | 2 | 2013 | 98 | 0.460 |
Why?
| Bone Marrow | 7 | 2022 | 408 | 0.460 |
Why?
| Animals | 28 | 2021 | 14247 | 0.450 |
Why?
| Meta-Analysis as Topic | 2 | 2015 | 38 | 0.440 |
Why?
| Osteoblasts | 4 | 2007 | 539 | 0.440 |
Why?
| Salvage Therapy | 9 | 2012 | 140 | 0.440 |
Why?
| Granulocyte Colony-Stimulating Factor | 2 | 2008 | 65 | 0.440 |
Why?
| Hematopoietic Stem Cells | 2 | 2010 | 232 | 0.430 |
Why?
| Risk Factors | 18 | 2018 | 3860 | 0.430 |
Why?
| Bone Marrow Transplantation | 5 | 2007 | 165 | 0.420 |
Why?
| Ultrasonography, Doppler | 2 | 2007 | 58 | 0.410 |
Why?
| Remission Induction | 10 | 2008 | 217 | 0.410 |
Why?
| Enzyme Inhibitors | 2 | 2019 | 439 | 0.400 |
Why?
| Membrane Proteins | 4 | 2017 | 376 | 0.400 |
Why?
| Prospective Studies | 9 | 2019 | 2349 | 0.400 |
Why?
| Myelodysplastic Syndromes | 4 | 2007 | 83 | 0.400 |
Why?
| Neoplasm, Residual | 4 | 2022 | 172 | 0.400 |
Why?
| Clinical Trials as Topic | 8 | 2007 | 483 | 0.390 |
Why?
| Cell Cycle Proteins | 2 | 2021 | 193 | 0.390 |
Why?
| B-Lymphocytes | 4 | 2021 | 183 | 0.390 |
Why?
| Waldenstrom Macroglobulinemia | 3 | 2018 | 34 | 0.390 |
Why?
| Lymphoma, B-Cell | 3 | 2021 | 60 | 0.380 |
Why?
| Immunosuppressive Agents | 3 | 2005 | 251 | 0.370 |
Why?
| Neovascularization, Pathologic | 1 | 2009 | 172 | 0.370 |
Why?
| Bone Neoplasms | 1 | 2010 | 194 | 0.360 |
Why?
| Brain Diseases, Metabolic | 1 | 2007 | 7 | 0.350 |
Why?
| Hyperammonemia | 1 | 2007 | 17 | 0.350 |
Why?
| Proteasome Endopeptidase Complex | 4 | 2018 | 133 | 0.340 |
Why?
| Chromosome Deletion | 3 | 2008 | 146 | 0.340 |
Why?
| Mice | 17 | 2021 | 6232 | 0.340 |
Why?
| Farnesyltranstransferase | 1 | 2006 | 3 | 0.340 |
Why?
| Thrombophilia | 4 | 2009 | 23 | 0.340 |
Why?
| Amyloidosis | 2 | 2007 | 81 | 0.340 |
Why?
| Research Design | 1 | 2009 | 342 | 0.340 |
Why?
| Peripheral Blood Stem Cell Transplantation | 4 | 2014 | 58 | 0.330 |
Why?
| Small Molecule Libraries | 2 | 2019 | 73 | 0.330 |
Why?
| Hemostasis | 1 | 2007 | 65 | 0.330 |
Why?
| Dose-Response Relationship, Drug | 6 | 2016 | 1550 | 0.320 |
Why?
| Sirolimus | 1 | 2006 | 62 | 0.320 |
Why?
| Aged, 80 and over | 11 | 2019 | 3496 | 0.320 |
Why?
| Gastrointestinal Neoplasms | 1 | 2006 | 37 | 0.320 |
Why?
| Bone and Bones | 1 | 2010 | 512 | 0.320 |
Why?
| In Situ Hybridization, Fluorescence | 6 | 2016 | 273 | 0.300 |
Why?
| Cell Survival | 8 | 2018 | 680 | 0.300 |
Why?
| Diploidy | 2 | 2004 | 31 | 0.300 |
Why?
| beta 2-Microglobulin | 5 | 2008 | 40 | 0.300 |
Why?
| Caspases | 1 | 2006 | 154 | 0.300 |
Why?
| Antibody Formation | 1 | 2005 | 65 | 0.290 |
Why?
| Activated Protein C Resistance | 4 | 2011 | 11 | 0.290 |
Why?
| Killer Cells, Natural | 3 | 2012 | 106 | 0.290 |
Why?
| Religion | 1 | 2005 | 70 | 0.290 |
Why?
| Aneuploidy | 1 | 2004 | 21 | 0.290 |
Why?
| Flow Cytometry | 6 | 2018 | 581 | 0.290 |
Why?
| Enoxaparin | 1 | 2004 | 24 | 0.290 |
Why?
| Case-Control Studies | 10 | 2018 | 1224 | 0.280 |
Why?
| Immunotherapy, Adoptive | 3 | 2012 | 76 | 0.270 |
Why?
| Ubiquitination | 2 | 2021 | 49 | 0.270 |
Why?
| Adaptation, Psychological | 1 | 2005 | 223 | 0.270 |
Why?
| Attitude to Health | 1 | 2005 | 231 | 0.260 |
Why?
| Randomized Controlled Trials as Topic | 4 | 2012 | 506 | 0.260 |
Why?
| Cell Communication | 2 | 2006 | 72 | 0.260 |
Why?
| Pyrimidines | 3 | 2015 | 188 | 0.250 |
Why?
| T-Lymphocytes | 6 | 2018 | 331 | 0.250 |
Why?
| Cancer Vaccines | 3 | 2010 | 102 | 0.250 |
Why?
| Multivariate Analysis | 5 | 2008 | 678 | 0.250 |
Why?
| Mice, Inbred NOD | 6 | 2020 | 99 | 0.250 |
Why?
| Antigens, CD34 | 1 | 2003 | 83 | 0.250 |
Why?
| Blood Coagulation | 1 | 2003 | 78 | 0.250 |
Why?
| Cytogenetic Analysis | 6 | 2007 | 78 | 0.250 |
Why?
| Cisplatin | 6 | 2009 | 342 | 0.250 |
Why?
| Graft vs Host Disease | 5 | 2010 | 83 | 0.250 |
Why?
| STAT3 Transcription Factor | 4 | 2015 | 84 | 0.240 |
Why?
| Leukemia, Myeloid | 1 | 2002 | 58 | 0.240 |
Why?
| Cyclophosphamide | 4 | 2003 | 190 | 0.240 |
Why?
| Critical Illness | 1 | 2005 | 315 | 0.240 |
Why?
| Chromosome Disorders | 1 | 2002 | 39 | 0.240 |
Why?
| Etoposide | 5 | 2009 | 90 | 0.230 |
Why?
| Neoplasms, Second Primary | 1 | 2002 | 72 | 0.230 |
Why?
| Hypothyroidism | 1 | 2002 | 49 | 0.230 |
Why?
| Parathyroid Hormone | 3 | 2010 | 220 | 0.230 |
Why?
| Kidney | 1 | 2007 | 754 | 0.230 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2015 | 100 | 0.230 |
Why?
| Chromosomes, Human, Pair 1 | 3 | 2006 | 99 | 0.220 |
Why?
| Logistic Models | 5 | 2018 | 1001 | 0.220 |
Why?
| Neoplasms | 2 | 2009 | 1143 | 0.210 |
Why?
| Cytotoxicity, Immunologic | 3 | 2012 | 62 | 0.210 |
Why?
| Time Factors | 9 | 2016 | 3352 | 0.210 |
Why?
| Xenograft Model Antitumor Assays | 5 | 2019 | 206 | 0.210 |
Why?
| Glucuronidase | 2 | 2018 | 50 | 0.200 |
Why?
| Hematologic Neoplasms | 2 | 2016 | 88 | 0.200 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2013 | 141 | 0.200 |
Why?
| DNA-Binding Proteins | 2 | 2020 | 493 | 0.190 |
Why?
| Syndecan-1 | 3 | 2017 | 82 | 0.190 |
Why?
| Predictive Value of Tests | 5 | 2009 | 1044 | 0.190 |
Why?
| Hydrocarbons, Aromatic | 1 | 2018 | 3 | 0.190 |
Why?
| Drug Tolerance | 1 | 2018 | 61 | 0.190 |
Why?
| Jehovah's Witnesses | 1 | 2018 | 7 | 0.190 |
Why?
| Solvents | 1 | 2018 | 39 | 0.190 |
Why?
| Kaplan-Meier Estimate | 6 | 2015 | 529 | 0.190 |
Why?
| Pyridines | 1 | 2019 | 138 | 0.190 |
Why?
| T-Lymphocytes, Cytotoxic | 3 | 2010 | 76 | 0.190 |
Why?
| Vincristine | 3 | 2003 | 94 | 0.180 |
Why?
| Cytokines | 4 | 2007 | 671 | 0.180 |
Why?
| Dendritic Cells | 3 | 2010 | 148 | 0.180 |
Why?
| CDC2-CDC28 Kinases | 2 | 2015 | 14 | 0.180 |
Why?
| Platelet Count | 3 | 2008 | 77 | 0.180 |
Why?
| Iron | 2 | 2017 | 144 | 0.170 |
Why?
| Arsenicals | 2 | 2010 | 14 | 0.170 |
Why?
| Pyruvate Kinase | 1 | 2017 | 8 | 0.170 |
Why?
| Drug Combinations | 1 | 2017 | 128 | 0.170 |
Why?
| Oxides | 2 | 2010 | 20 | 0.170 |
Why?
| Occupational Diseases | 1 | 2018 | 98 | 0.170 |
Why?
| Ascorbic Acid | 1 | 2017 | 34 | 0.170 |
Why?
| Mice, SCID | 5 | 2018 | 199 | 0.170 |
Why?
| RNA Splicing | 1 | 2017 | 34 | 0.170 |
Why?
| Interleukin-6 | 2 | 2018 | 299 | 0.170 |
Why?
| Anthropometry | 1 | 2017 | 96 | 0.170 |
Why?
| Occupational Exposure | 1 | 2018 | 137 | 0.160 |
Why?
| Glycolysis | 1 | 2017 | 64 | 0.160 |
Why?
| Neoplasm Recurrence, Local | 3 | 2022 | 576 | 0.160 |
Why?
| Factor V | 3 | 2011 | 13 | 0.160 |
Why?
| Immunoglobulin lambda-Chains | 1 | 2016 | 16 | 0.160 |
Why?
| Immunoglobulin kappa-Chains | 1 | 2016 | 31 | 0.160 |
Why?
| Oncolytic Virotherapy | 1 | 2015 | 12 | 0.160 |
Why?
| Reproductive History | 1 | 2015 | 4 | 0.160 |
Why?
| Immunotherapy | 4 | 2006 | 241 | 0.160 |
Why?
| Tumor Cells, Cultured | 6 | 2019 | 508 | 0.160 |
Why?
| Leukocytes, Mononuclear | 2 | 2014 | 124 | 0.160 |
Why?
| Incidence | 3 | 2009 | 1051 | 0.160 |
Why?
| Hormone Replacement Therapy | 1 | 2015 | 21 | 0.160 |
Why?
| Fibrinolytic Agents | 2 | 2007 | 138 | 0.160 |
Why?
| Transcription Factors | 1 | 2020 | 618 | 0.150 |
Why?
| MicroRNAs | 1 | 2020 | 358 | 0.150 |
Why?
| Cyclopentanes | 1 | 2015 | 16 | 0.150 |
Why?
| Cell Adhesion Molecules | 1 | 2015 | 96 | 0.150 |
Why?
| Ubiquitins | 1 | 2015 | 39 | 0.150 |
Why?
| Hemorrhage | 2 | 2007 | 190 | 0.150 |
Why?
| Cation Transport Proteins | 1 | 2015 | 27 | 0.150 |
Why?
| Aldehyde Dehydrogenase | 1 | 2014 | 28 | 0.150 |
Why?
| Postmenopause | 1 | 2015 | 83 | 0.150 |
Why?
| Receptors, Cell Surface | 1 | 2015 | 137 | 0.140 |
Why?
| Leukapheresis | 1 | 2014 | 15 | 0.140 |
Why?
| Drug Monitoring | 1 | 2015 | 90 | 0.140 |
Why?
| Transplantation Chimera | 3 | 2003 | 17 | 0.140 |
Why?
| NF-kappa B | 3 | 2018 | 335 | 0.140 |
Why?
| Osteoclasts | 3 | 2015 | 443 | 0.140 |
Why?
| Protein-Tyrosine Kinases | 1 | 2015 | 103 | 0.140 |
Why?
| Myeloma Proteins | 2 | 2020 | 29 | 0.140 |
Why?
| Translocation, Genetic | 3 | 2005 | 278 | 0.140 |
Why?
| Intestines | 1 | 2016 | 207 | 0.140 |
Why?
| Receptor, Parathyroid Hormone, Type 1 | 1 | 2013 | 32 | 0.140 |
Why?
| Veratrum Alkaloids | 1 | 2013 | 4 | 0.140 |
Why?
| Gene Deletion | 3 | 2004 | 278 | 0.130 |
Why?
| Isoxazoles | 1 | 2013 | 14 | 0.130 |
Why?
| Multidrug Resistance-Associated Proteins | 1 | 2013 | 16 | 0.130 |
Why?
| Body Mass Index | 1 | 2017 | 676 | 0.130 |
Why?
| Sulfones | 1 | 2013 | 22 | 0.130 |
Why?
| Hedgehog Proteins | 1 | 2013 | 34 | 0.130 |
Why?
| Itraconazole | 1 | 2013 | 41 | 0.130 |
Why?
| Metaphase | 3 | 2008 | 57 | 0.130 |
Why?
| Tumor Microenvironment | 1 | 2014 | 137 | 0.130 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2013 | 75 | 0.130 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2016 | 544 | 0.130 |
Why?
| Biopsy | 2 | 2006 | 686 | 0.130 |
Why?
| Wnt Proteins | 1 | 2013 | 109 | 0.130 |
Why?
| Carrier Proteins | 2 | 2017 | 358 | 0.130 |
Why?
| Genetic Predisposition to Disease | 1 | 2016 | 564 | 0.120 |
Why?
| Cell Differentiation | 3 | 2018 | 750 | 0.120 |
Why?
| Renal Insufficiency | 3 | 2009 | 134 | 0.120 |
Why?
| Viremia | 1 | 2012 | 22 | 0.120 |
Why?
| Infusions, Intravenous | 2 | 2003 | 243 | 0.120 |
Why?
| Risk | 2 | 2011 | 342 | 0.120 |
Why?
| Chromosomes, Human, Pair 11 | 2 | 2002 | 61 | 0.120 |
Why?
| Risk Assessment | 4 | 2016 | 1387 | 0.120 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2012 | 45 | 0.120 |
Why?
| Cytomegalovirus Infections | 1 | 2012 | 45 | 0.120 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2012 | 52 | 0.120 |
Why?
| Drug Delivery Systems | 2 | 2005 | 152 | 0.120 |
Why?
| Receptors, KIR | 2 | 2008 | 16 | 0.120 |
Why?
| Fluorodeoxyglucose F18 | 2 | 2021 | 199 | 0.120 |
Why?
| Reoperation | 2 | 2004 | 443 | 0.120 |
Why?
| Medical Oncology | 1 | 2012 | 89 | 0.120 |
Why?
| Ligands | 2 | 2009 | 248 | 0.110 |
Why?
| Radiopharmaceuticals | 2 | 2021 | 252 | 0.110 |
Why?
| Phosphorylation | 2 | 2020 | 620 | 0.110 |
Why?
| Drug Evaluation, Preclinical | 1 | 2012 | 157 | 0.110 |
Why?
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 5 | 0.110 |
Why?
| Tretinoin | 2 | 2009 | 63 | 0.110 |
Why?
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 22 | 0.110 |
Why?
| Alcohol Drinking | 1 | 2013 | 261 | 0.110 |
Why?
| Inflammation | 1 | 2016 | 635 | 0.110 |
Why?
| Antineoplastic Agents, Hormonal | 2 | 2007 | 54 | 0.110 |
Why?
| Monoclonal Gammopathy of Undetermined Significance | 2 | 2011 | 77 | 0.110 |
Why?
| Age Factors | 3 | 2005 | 1226 | 0.110 |
Why?
| Janus Kinase 1 | 1 | 2010 | 21 | 0.110 |
Why?
| Cyclin-Dependent Kinases | 1 | 2010 | 31 | 0.110 |
Why?
| MAP Kinase Kinase 1 | 1 | 2010 | 27 | 0.110 |
Why?
| Recombinant Proteins | 2 | 2010 | 583 | 0.100 |
Why?
| Authorship | 1 | 2010 | 14 | 0.100 |
Why?
| Smoking | 1 | 2014 | 554 | 0.100 |
Why?
| Conflict of Interest | 1 | 2010 | 22 | 0.100 |
Why?
| Drug Industry | 1 | 2010 | 40 | 0.100 |
Why?
| Macrophages | 1 | 2013 | 390 | 0.100 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 110 | 0.100 |
Why?
| Down-Regulation | 2 | 2010 | 396 | 0.100 |
Why?
| Bone Density Conservation Agents | 1 | 2010 | 82 | 0.100 |
Why?
| Neoplasm Staging | 3 | 2015 | 792 | 0.100 |
Why?
| Disclosure | 1 | 2010 | 42 | 0.100 |
Why?
| Chromosome Banding | 2 | 2006 | 27 | 0.100 |
Why?
| Diphosphonates | 1 | 2010 | 97 | 0.100 |
Why?
| Leukocyte Count | 2 | 2014 | 82 | 0.100 |
Why?
| Plasmacytoma | 2 | 2011 | 43 | 0.100 |
Why?
| Maximum Tolerated Dose | 2 | 2009 | 38 | 0.100 |
Why?
| Periodicals as Topic | 1 | 2010 | 65 | 0.100 |
Why?
| Cryoglobulinemia | 1 | 2008 | 12 | 0.100 |
Why?
| Cell Cycle | 2 | 2010 | 270 | 0.090 |
Why?
| Mice, Transgenic | 3 | 2021 | 724 | 0.090 |
Why?
| Oligonucleotide Array Sequence Analysis | 5 | 2014 | 477 | 0.090 |
Why?
| Cytogenetics | 1 | 2008 | 27 | 0.090 |
Why?
| Prednisone | 2 | 2009 | 115 | 0.090 |
Why?
| Blotting, Western | 3 | 2015 | 704 | 0.090 |
Why?
| Pulmonary Embolism | 1 | 2009 | 93 | 0.090 |
Why?
| Hemoglobins | 1 | 2008 | 113 | 0.090 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2009 | 220 | 0.090 |
Why?
| Magnetic Resonance Imaging | 3 | 2007 | 1592 | 0.090 |
Why?
| Neutrophils | 2 | 2014 | 161 | 0.090 |
Why?
| Adoptive Transfer | 1 | 2007 | 39 | 0.090 |
Why?
| Sulfonamides | 1 | 2009 | 141 | 0.090 |
Why?
| Polyethylene Glycols | 1 | 2008 | 94 | 0.090 |
Why?
| Heparin, Low-Molecular-Weight | 1 | 2007 | 22 | 0.090 |
Why?
| Immunophenotyping | 2 | 2007 | 128 | 0.090 |
Why?
| Histocompatibility Antigens Class I | 1 | 2007 | 44 | 0.090 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 699 | 0.090 |
Why?
| Phlebography | 1 | 2007 | 72 | 0.090 |
Why?
| Fibrinolysis | 1 | 2007 | 11 | 0.090 |
Why?
| Ammonia | 1 | 2007 | 71 | 0.090 |
Why?
| Blood Coagulation Factors | 1 | 2007 | 18 | 0.090 |
Why?
| Serum Albumin | 2 | 2008 | 65 | 0.080 |
Why?
| Chi-Square Distribution | 1 | 2007 | 328 | 0.080 |
Why?
| Biomedical Research | 1 | 2010 | 230 | 0.080 |
Why?
| Osteoprotegerin | 1 | 2006 | 53 | 0.080 |
Why?
| Guanosine | 1 | 2006 | 6 | 0.080 |
Why?
| Drug Administration Schedule | 2 | 2006 | 420 | 0.080 |
Why?
| Cell Membrane | 1 | 2007 | 271 | 0.080 |
Why?
| Models, Genetic | 1 | 2006 | 195 | 0.080 |
Why?
| Antibiotics, Antineoplastic | 1 | 2006 | 85 | 0.080 |
Why?
| Femur Head Necrosis | 1 | 2005 | 16 | 0.080 |
Why?
| Brain | 2 | 2007 | 1378 | 0.080 |
Why?
| Survivors | 1 | 2006 | 104 | 0.080 |
Why?
| Neovascularization, Physiologic | 1 | 2005 | 73 | 0.070 |
Why?
| Guanosine Triphosphate | 1 | 2004 | 21 | 0.070 |
Why?
| Kidney Transplantation | 1 | 2007 | 161 | 0.070 |
Why?
| Sex Factors | 3 | 2016 | 781 | 0.070 |
Why?
| Renal Dialysis | 1 | 2007 | 174 | 0.070 |
Why?
| Gene Duplication | 1 | 2005 | 16 | 0.070 |
Why?
| Karyotyping | 1 | 2005 | 99 | 0.070 |
Why?
| Tissue Donors | 2 | 2003 | 97 | 0.070 |
Why?
| Oncogene Proteins, Fusion | 1 | 2005 | 62 | 0.070 |
Why?
| Thrombophlebitis | 1 | 2004 | 30 | 0.070 |
Why?
| Proteolysis | 2 | 2015 | 96 | 0.070 |
Why?
| Genomic Instability | 1 | 2005 | 93 | 0.070 |
Why?
| Tomography, Emission-Computed | 1 | 2004 | 70 | 0.070 |
Why?
| Antibodies | 1 | 2005 | 172 | 0.070 |
Why?
| RNA Interference | 2 | 2015 | 201 | 0.070 |
Why?
| Anxiety | 1 | 2005 | 252 | 0.070 |
Why?
| Discitis | 1 | 2003 | 8 | 0.070 |
Why?
| Stem Cell Factor | 1 | 2003 | 8 | 0.070 |
Why?
| Lymphocyte Transfusion | 1 | 2003 | 13 | 0.060 |
Why?
| Confidence Intervals | 1 | 2003 | 178 | 0.060 |
Why?
| Probability | 1 | 2003 | 185 | 0.060 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2004 | 440 | 0.060 |
Why?
| Interferons | 1 | 2002 | 36 | 0.060 |
Why?
| Patient Selection | 1 | 2005 | 292 | 0.060 |
Why?
| Neoplastic Cells, Circulating | 1 | 2004 | 93 | 0.060 |
Why?
| Cyclosporine | 1 | 2003 | 67 | 0.060 |
Why?
| Tacrolimus | 1 | 2003 | 39 | 0.060 |
Why?
| Cell Count | 1 | 2003 | 192 | 0.060 |
Why?
| Thyroid Function Tests | 1 | 2002 | 27 | 0.060 |
Why?
| Blood Group Incompatibility | 1 | 2002 | 4 | 0.060 |
Why?
| Drug Therapy, Combination | 2 | 2017 | 423 | 0.060 |
Why?
| ABO Blood-Group System | 1 | 2002 | 14 | 0.060 |
Why?
| Thyrotropin | 1 | 2002 | 42 | 0.060 |
Why?
| Leukemia, Promyelocytic, Acute | 1 | 2002 | 11 | 0.060 |
Why?
| Administration, Oral | 1 | 2003 | 459 | 0.060 |
Why?
| Stromal Cells | 1 | 2002 | 98 | 0.060 |
Why?
| Drug Interactions | 1 | 2002 | 215 | 0.060 |
Why?
| Fatal Outcome | 1 | 2002 | 231 | 0.060 |
Why?
| Chromosome Mapping | 3 | 2006 | 165 | 0.060 |
Why?
| Graft Survival | 1 | 2002 | 163 | 0.060 |
Why?
| Cell Division | 1 | 2002 | 366 | 0.060 |
Why?
| Acute Disease | 1 | 2002 | 411 | 0.060 |
Why?
| Cluster Analysis | 3 | 2006 | 249 | 0.050 |
Why?
| Neoplasm Transplantation | 1 | 2020 | 92 | 0.050 |
Why?
| Cells, Cultured | 1 | 2005 | 1787 | 0.050 |
Why?
| Young Adult | 3 | 2015 | 4120 | 0.050 |
Why?
| 3' Untranslated Regions | 1 | 2020 | 55 | 0.050 |
Why?
| Depression | 1 | 2005 | 559 | 0.050 |
Why?
| Tomography, X-Ray Computed | 1 | 2006 | 1235 | 0.050 |
Why?
| Odds Ratio | 2 | 2016 | 606 | 0.050 |
Why?
| Pain | 1 | 2003 | 362 | 0.050 |
Why?
| Positron-Emission Tomography | 1 | 2021 | 311 | 0.050 |
Why?
| Crystallography, X-Ray | 1 | 2019 | 160 | 0.050 |
Why?
| Postoperative Complications | 1 | 2007 | 1005 | 0.050 |
Why?
| Staphylococcal Infections | 1 | 2003 | 291 | 0.050 |
Why?
| Mice, Nude | 1 | 2019 | 270 | 0.050 |
Why?
| Protein Conformation | 1 | 2019 | 214 | 0.050 |
Why?
| Antigens, CD | 2 | 2015 | 264 | 0.050 |
Why?
| Coculture Techniques | 2 | 2012 | 161 | 0.050 |
Why?
| Antigens, CD19 | 1 | 2018 | 22 | 0.050 |
Why?
| Receptors, Interleukin-6 | 1 | 2018 | 31 | 0.050 |
Why?
| Mice, Inbred BALB C | 1 | 2019 | 370 | 0.050 |
Why?
| Bone Marrow Cells | 2 | 2015 | 250 | 0.050 |
Why?
| Microarray Analysis | 1 | 2018 | 83 | 0.050 |
Why?
| Drug Resistance | 1 | 2018 | 80 | 0.050 |
Why?
| Protein Stability | 1 | 2018 | 47 | 0.050 |
Why?
| Interferon-gamma | 2 | 2010 | 194 | 0.050 |
Why?
| Gene Knockdown Techniques | 1 | 2018 | 128 | 0.050 |
Why?
| Disease Management | 1 | 2020 | 198 | 0.050 |
Why?
| Vaccination | 2 | 2010 | 156 | 0.040 |
Why?
| Epidemiologic Methods | 2 | 2008 | 50 | 0.040 |
Why?
| Aerobiosis | 1 | 2017 | 15 | 0.040 |
Why?
| HLA-A Antigens | 2 | 2007 | 14 | 0.040 |
Why?
| Transplantation, Heterologous | 1 | 2017 | 80 | 0.040 |
Why?
| Microfilament Proteins | 1 | 2017 | 52 | 0.040 |
Why?
| Thyroid Hormones | 1 | 2017 | 21 | 0.040 |
Why?
| Calcium-Binding Proteins | 1 | 2017 | 59 | 0.040 |
Why?
| Transmembrane Activator and CAML Interactor Protein | 1 | 2016 | 3 | 0.040 |
Why?
| Polycomb Repressive Complex 1 | 1 | 2016 | 5 | 0.040 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 2017 | 56 | 0.040 |
Why?
| Genetic Loci | 1 | 2016 | 62 | 0.040 |
Why?
| Mice, Inbred ICR | 1 | 2016 | 27 | 0.040 |
Why?
| Antibodies, Neoplasm | 2 | 2006 | 38 | 0.040 |
Why?
| Microscopy, Electron, Transmission | 1 | 2015 | 86 | 0.040 |
Why?
| Protein Binding | 1 | 2018 | 756 | 0.040 |
Why?
| Reoviridae | 1 | 2015 | 28 | 0.040 |
Why?
| ras Proteins | 1 | 2015 | 69 | 0.040 |
Why?
| Tumor Burden | 1 | 2016 | 142 | 0.040 |
Why?
| Genome-Wide Association Study | 1 | 2016 | 191 | 0.040 |
Why?
| Receptors, Transferrin | 1 | 2015 | 12 | 0.040 |
Why?
| Mice, Knockout | 1 | 2018 | 980 | 0.040 |
Why?
| Side-Population Cells | 1 | 2015 | 2 | 0.040 |
Why?
| Retinal Dehydrogenase | 1 | 2014 | 9 | 0.040 |
Why?
| Lentivirus | 1 | 2015 | 17 | 0.040 |
Why?
| G2 Phase Cell Cycle Checkpoints | 1 | 2014 | 9 | 0.040 |
Why?
| Cyclin B | 1 | 2014 | 6 | 0.040 |
Why?
| Adenine | 1 | 2015 | 44 | 0.040 |
Why?
| Portraits as Topic | 1 | 2014 | 2 | 0.040 |
Why?
| CDC2 Protein Kinase | 1 | 2014 | 23 | 0.040 |
Why?
| Repressor Proteins | 1 | 2016 | 170 | 0.040 |
Why?
| Molecular Targeted Therapy | 1 | 2016 | 134 | 0.040 |
Why?
| Family | 1 | 2016 | 184 | 0.040 |
Why?
| Cell Lineage | 1 | 2014 | 99 | 0.040 |
Why?
| RNA, Messenger | 2 | 2010 | 1239 | 0.040 |
Why?
| Drug Synergism | 1 | 2014 | 168 | 0.030 |
Why?
| Piperidines | 1 | 2015 | 102 | 0.030 |
Why?
| beta Catenin | 1 | 2015 | 98 | 0.030 |
Why?
| Reactive Oxygen Species | 1 | 2017 | 504 | 0.030 |
Why?
| Mitosis | 1 | 2014 | 103 | 0.030 |
Why?
| Disease Models, Animal | 2 | 2013 | 1638 | 0.030 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2014 | 144 | 0.030 |
Why?
| Pyrazoles | 1 | 2015 | 118 | 0.030 |
Why?
| Models, Biological | 1 | 2018 | 842 | 0.030 |
Why?
| Peptide Library | 1 | 2013 | 27 | 0.030 |
Why?
| Proportional Hazards Models | 2 | 2006 | 450 | 0.030 |
Why?
| Receptors, IgG | 1 | 2013 | 23 | 0.030 |
Why?
| Cell Movement | 1 | 2015 | 300 | 0.030 |
Why?
| Patient Safety | 1 | 2014 | 124 | 0.030 |
Why?
| Chromosomal Instability | 1 | 2013 | 19 | 0.030 |
Why?
| Epitopes | 1 | 2013 | 84 | 0.030 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 54 | 0.030 |
Why?
| Membrane Glycoproteins | 2 | 2006 | 291 | 0.030 |
Why?
| Bone Resorption | 1 | 2015 | 300 | 0.030 |
Why?
| Protein Kinase Inhibitors | 1 | 2014 | 204 | 0.030 |
Why?
| Immunoglobulin M | 1 | 2012 | 59 | 0.030 |
Why?
| Interleukin Receptor Common gamma Subunit | 1 | 2012 | 10 | 0.030 |
Why?
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2012 | 11 | 0.030 |
Why?
| Cytomegalovirus | 1 | 2012 | 28 | 0.030 |
Why?
| Adolescent | 2 | 2014 | 6596 | 0.030 |
Why?
| Virus Activation | 1 | 2012 | 29 | 0.030 |
Why?
| Interleukin-2 | 1 | 2012 | 80 | 0.030 |
Why?
| Viral Load | 1 | 2012 | 86 | 0.030 |
Why?
| Peripheral Nervous System Diseases | 1 | 2012 | 60 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 173 | 0.030 |
Why?
| Russell's Viper | 1 | 2011 | 3 | 0.030 |
Why?
| Viper Venoms | 1 | 2011 | 6 | 0.030 |
Why?
| Asymptomatic Diseases | 1 | 2011 | 41 | 0.030 |
Why?
| Osteolysis | 1 | 2012 | 79 | 0.030 |
Why?
| Protein C | 1 | 2011 | 25 | 0.030 |
Why?
| Neoadjuvant Therapy | 1 | 2012 | 114 | 0.030 |
Why?
| Chemotherapy, Adjuvant | 1 | 2011 | 130 | 0.030 |
Why?
| Arkansas | 2 | 2008 | 2133 | 0.030 |
Why?
| Lymphocyte Activation | 1 | 2012 | 211 | 0.030 |
Why?
| Interferon Regulatory Factor-1 | 1 | 2010 | 12 | 0.030 |
Why?
| Cell Growth Processes | 1 | 2010 | 24 | 0.030 |
Why?
| CD40 Ligand | 1 | 2010 | 17 | 0.030 |
Why?
| Immunoglobulin Idiotypes | 1 | 2010 | 18 | 0.030 |
Why?
| Hypersensitivity, Delayed | 1 | 2010 | 21 | 0.030 |
Why?
| Interleukin-4 | 1 | 2010 | 48 | 0.030 |
Why?
| Antiviral Agents | 1 | 2012 | 187 | 0.030 |
Why?
| Immunity, Cellular | 1 | 2010 | 82 | 0.030 |
Why?
| Adjuvants, Immunologic | 1 | 2010 | 62 | 0.030 |
Why?
| Physician's Role | 1 | 2010 | 58 | 0.030 |
Why?
| Hyperhomocysteinemia | 1 | 2009 | 32 | 0.020 |
Why?
| RNA, Small Interfering | 1 | 2010 | 267 | 0.020 |
Why?
| Education, Medical, Continuing | 1 | 2010 | 82 | 0.020 |
Why?
| Diagnosis, Differential | 2 | 2004 | 1151 | 0.020 |
Why?
| Indazoles | 1 | 2009 | 49 | 0.020 |
Why?
| Cytotoxicity Tests, Immunologic | 1 | 2008 | 30 | 0.020 |
Why?
| Mutation | 1 | 2015 | 1361 | 0.020 |
Why?
| Protein Isoforms | 1 | 2009 | 134 | 0.020 |
Why?
| Vasculitis | 1 | 2008 | 32 | 0.020 |
Why?
| Practice Guidelines as Topic | 1 | 2012 | 522 | 0.020 |
Why?
| Safety | 1 | 2009 | 98 | 0.020 |
Why?
| Ploidies | 1 | 2008 | 13 | 0.020 |
Why?
| Haplotypes | 1 | 2008 | 101 | 0.020 |
Why?
| Algorithms | 1 | 2012 | 690 | 0.020 |
Why?
| Twins | 1 | 2007 | 33 | 0.020 |
Why?
| Double-Blind Method | 1 | 2009 | 733 | 0.020 |
Why?
| Age Distribution | 1 | 2007 | 193 | 0.020 |
Why?
| C-Reactive Protein | 1 | 2008 | 159 | 0.020 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2007 | 110 | 0.020 |
Why?
| Multigene Family | 1 | 2006 | 64 | 0.020 |
Why?
| Creatinine | 1 | 2007 | 161 | 0.020 |
Why?
| Partial Thromboplastin Time | 1 | 2006 | 12 | 0.020 |
Why?
| Blood Proteins | 1 | 2007 | 100 | 0.020 |
Why?
| Cyclin D | 1 | 2006 | 21 | 0.020 |
Why?
| Syndecans | 1 | 2006 | 46 | 0.020 |
Why?
| Heterozygote | 1 | 2006 | 84 | 0.020 |
Why?
| RNA, Neoplasm | 1 | 2006 | 58 | 0.020 |
Why?
| Cyclins | 1 | 2006 | 56 | 0.020 |
Why?
| HLA-A2 Antigen | 1 | 2005 | 12 | 0.020 |
Why?
| Amiloride | 1 | 2005 | 12 | 0.020 |
Why?
| Proteoglycans | 1 | 2006 | 96 | 0.020 |
Why?
| Transduction, Genetic | 1 | 2005 | 52 | 0.020 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2007 | 176 | 0.020 |
Why?
| Radiography | 1 | 2007 | 525 | 0.020 |
Why?
| Data Interpretation, Statistical | 1 | 2006 | 177 | 0.020 |
Why?
| Interferon-alpha | 1 | 2005 | 54 | 0.020 |
Why?
| Neoplasms, Experimental | 1 | 2006 | 117 | 0.020 |
Why?
| Cell Line | 1 | 2008 | 1205 | 0.020 |
Why?
| Monocytes | 1 | 2005 | 157 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2007 | 953 | 0.020 |
Why?
| Databases, Factual | 1 | 2007 | 677 | 0.020 |
Why?
| Clone Cells | 1 | 2004 | 86 | 0.020 |
Why?
| Monosomy | 1 | 2003 | 5 | 0.020 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2005 | 219 | 0.020 |
Why?
| Trisomy | 1 | 2003 | 34 | 0.020 |
Why?
| History, 21st Century | 1 | 2003 | 68 | 0.020 |
Why?
| Interphase | 1 | 2003 | 14 | 0.020 |
Why?
| Plasmapheresis | 1 | 2003 | 14 | 0.020 |
Why?
| Fibroblasts | 1 | 2005 | 376 | 0.020 |
Why?
| History, 20th Century | 1 | 2003 | 126 | 0.020 |
Why?
| Back Pain | 1 | 2003 | 42 | 0.020 |
Why?
| Pore Forming Cytotoxic Proteins | 1 | 2002 | 9 | 0.020 |
Why?
| Perforin | 1 | 2002 | 11 | 0.020 |
Why?
| Antigen Presentation | 1 | 2002 | 25 | 0.020 |
Why?
| Red-Cell Aplasia, Pure | 1 | 2002 | 9 | 0.020 |
Why?
| United States | 1 | 2013 | 4825 | 0.020 |
Why?
| Anemia | 1 | 2003 | 92 | 0.020 |
Why?
| Cohort Studies | 1 | 2006 | 1444 | 0.010 |
Why?
| Prevalence | 1 | 2005 | 944 | 0.010 |
Why?
| Quality Assurance, Health Care | 1 | 2003 | 171 | 0.010 |
Why?
| Cell Culture Techniques | 1 | 2002 | 119 | 0.010 |
Why?
| DNA, Neoplasm | 1 | 2002 | 177 | 0.010 |
Why?
| Erythrocyte Transfusion | 1 | 2002 | 86 | 0.010 |
Why?
| Graft Rejection | 1 | 2002 | 158 | 0.010 |
Why?
| Kidney Diseases | 1 | 2003 | 279 | 0.010 |
Why?
| Anti-Bacterial Agents | 1 | 2003 | 756 | 0.010 |
Why?
|
|
Tricot's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|